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Abstract 
Lung injury with severe respiratory failure is the leading cause of death in COVID-19. 
Inhibition of ACE2 caused by spike protein of (SARS)-CoV-2 is the most plausible mechanism 
of lung injury in COVID-19. We proposed six candidate drugs, including geldanamycin, 
panobinostat, trichostatin A, narciclasine, COL-3 and CGP-60474, that could best reverse 
abnormal gene expression caused by (SARS)-CoV-2-induced inhibition of ACE2 in lung cells, 
for the promise of treating lung injuries in COVID-19. 
  
Main 
Coronavirus disease (COVID-19) is an infectious disease discovered in 2019 and currently 
in outbreak across the world, resulting in more than 0.3 million infections and over fourteen 
thousand deaths by now. It is causing tens of thousands of new infections and thousands of 
mortalities every day. Severe viral pneumonia related lung injury with respiratory failure is the 
main reason of COVID-19 related death1.  
This novel coronavirus (CoV), termed severe acute respiratory synrdrome (SARS)-CoV-2, 
uses the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) for entry and the 
serine protease TMPRSS2 for S protein priming2. In SARS-CoV infection, viral spike protein 
inhibits ACE2 and causes severe lung injury3,4. Since the spike protein of (SARS)-CoV-2 
interacts with ACE2 as does the spike protein of SARS-CoV, inhibition of ACE2 may be the 
pathogenic mechanism in (SARS)-CoV-2 induced lung injury.  
Based on this assumption, we performed drug reposition analysis to identify drugs and 
compounds for treating (SARS)-CoV-2 induced lung injury. We collected differential gene 
expression profiles in HCC515 and A549 lung cells with the inhibition of ACE2 from LINCS 
L1000 project5. Then we analyzed 12,707 drugs and compounds from LINCS L1000 
pharmacogenomics data to find best candidates that could reverse abnormal gene 
expression. Upon examination of ACE2 expression at different time points (6h and 24h), we 
opted to focus on HCC515 cells which have reduced ACE2 expression over treatment of 
moexipril, an ACE2 inhibitor. At 6 h after treatment of moexipril, narciclasine (FDR=0.006) 
and geldanamycin (FDR=0.006) could significantly (FDR<0.05) recover abnormal gene 
expressions. At 24h post treatment of moexipril, CGP-60474 (FDR=1.337×10-7), 
panobinostat (FDR=2.443×10-05), trichostatin-a (FDR= 3.546×10-03) and COL-3 (FDR= 0.002)  
could significantly recover abnormal gene expression in HCC515 cell.  
In lung, the inhibition of ACE2 promote lung injury via the renin–angiotensin system (RAS)6. 
In pulmonary RAS, ACE2 converts angiotensin II (Ang II), an octapeptide hormone, to Ang-
(1-7), an heptapeptide hormone. Ang II is a pulmonary profibrotic mediator and stimulates 
procollagen production in lung fibroblasts to promote lung injury7. Ang-(1–7) protects lung 
from injury, through reducing both inflammatory response by lowering cytokine release8 and 
pulmonary fibrosis by inhibiting fibrotic signaling pathways9. Thus, inhibition of ACE2 will 
increase Ang II level and decrease Ang-(1–7), promote fibrosis and inflammation and injure 
lung tissues (Figure 1).  
Figure 1. Mechanisms of candidate drugs for treating lung injury in COVID-19. 
Among proposed candidate drugs, panobinostat and trichostatin-a were shown to inhibit 
pulmonary fibrosis10,11, while geldanamycin, COL-3 and narciclasine inhibit inflammation12-14, 
to attenuate lung injury in animal model (Figure 1). Panobinostat is a hydroxamic acid and 
can act as a non-selective histone deacetylase (HDAC) inhibitor. It was approved for the 
treatment of multiple myeloma. Panobinostat was reported to reduce pulmonary fibrosis by 
inducing cell cycle arrest and apoptosis in idiopathic pulmonary fibrosis fibroblasts10. 
Trichostatin A is an organic compound that serves as an antifungal antibiotic and selectively 
inhibits the class I and II mammalian HDACs, but not class III HDACs. It attenuated lung 
injury in various diseases15,16. Geldanamycin is an inhibitor of heat shock protein 90. It 
reduced H5N1 infection induced lung injury 12. Narciclasine is an isocarbostyril alkaloid found 
in the Amaryllidaceae (amaryllis) family of flowering plants. It can alleviate inflammatory 
responses and reduce lung injury in sepsis14. COL-3 is a chemically modified tetracycline that 
prevented lung injury and reduced morbidity associated with sepsis 13. COL-3 was used in 
clinical trials for the treatment of HIV Infection (Clinical trial: NCT00020683). CGP-60474, an 
inhibitor of cyclin-dependent kinase, is the only molecule that has no known relationship with 
lung injury.  
In summary, we propose the six candidate drugs above, which could be used to inhibit 
pulmonary fibrosis or inflammation and thus attenuate lung injury induced by (SARS)-CoV-2. 
It is our hope to solicit the interest of the biomedical community, to save more lives from 
severe respiratory failure in COVID-19. 
Methods and Materials 
Data Preparation 
We downloaded level 5 LINCS L1000 data, a collection of gene expression profiles for 
thousands of perturbagens at a variety of time points, doses, and cell lines, from Gene 
Expression Omnibus (GEO) database (GEO id: GSE70138 and GSE92742). Gene 
expression profiles in lung cells were extracted from downloaded dataset. The extracted data 
includes 37,366 treatments of 12,707 drugs in 13 lung cell lines at different time points and 
doses. There were two lung cell lines, A549 and HCC515, that were treated with 10 µM 
moexipril, an inhibitor of ACE2 and ACE, a homologue of ACE2. Gene expression profiles 
were collected from A549 and HCC515 cells at 6 and 24 h after treatment. Upon moexipril 
treatment, ACE2 level decreased with time in HCC515 but increased in A549, prompting us 
to focus the analysis using HCC515 line, which showed the inhibition effect of moexipril. The 
gene expression profiles used to simulate gene expressions in lung with the inhibition of 
ACE2 by spike protein of (SARS)-CoV-2. Differential expression of gene was obtained by 
comparing the sample cell to all other cells in the same plate after all cells’ gene expression 
being normalized by a z-scoring procedure. 
Drug Repurposing Analysis 
The differential gene expression of 12,328 genes, simulating (SARS)-CoV-2 related inhibition 
of ACE2 in lung, were transformed to a gene rank list. The reference dataset contains gene 
rank lists of treatments of 12,707 drugs from LINCS L1000 data as mentioned above. In our 
hypothesis, an effective drug treatment is one that reverts the aberrant gene expression back 
to the normal levels. Therefore, an outlier-sum (OS) based statistic was used to model the 
overall disease-drug connectivity by aggregating disease transcriptome changes with drug 
perturbation using DrInsight Package17. The Kolmogorov–Smirnov (K-S) test was used 
determine whether the OS from one drug is larger than those from the rest drugs and 
compounds in the reference dataset. 
Statistical Analysis 
The false discovery rate (FDR) method was used to adjust P-values from the K-S test to avoid 
false discovery in multiple comparisons. A drug with FDR<0.05 was selected as the candidate 
drug for the disease. 
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